https://www.selleckchem.com/pr....oducts/vps34-inhibit
81, 95% CI 0.70-0.89) and relapse-free survival (RFS, P 0.01) in the training cohort. The identified exo-miRNA panel was successfully validated in an independent validation cohort (AUC 0.78, 95% CI 0.65-0.88, RFS P 0.01), where it exhibited comparable performance in the post-NAT cohort (AUC 0.72, 95% CI 0.57-0.85, RFS P 0.01) and emerged as an independent predictor for RFS (HR 2.84, 95% CI 1.30-6.2. We identified a novel, non-invasive exosomal miRNA signature that robustly predicts recurrence following surgery
Aimer
Commentaire
Partagez
